Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: Phase II study

Bone Marrow Transplantation

Volumn 35, Issue 12, 2005, Pages 1165-1169

  Jagasia, Madan H ^a,b   Greer, J P ^a   Morgan, D S ^a   Mineishi, S ^a   Kassim, A A ^a   Ruffner, K L ^a   Chen, H ^a   Schuening, F G ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autologous stem cell transplant; Engraftment; Pegfilgrastim

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUCONAZOLE; GROWTH FACTOR; MELPHALAN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VALACICLOVIR;

ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GRAFT DYSFUNCTION; HEMORRHAGIC CYSTITIS; HUMAN; INCIDENCE; INFECTION; LYMPHOMA; MALE; MULTIPLE MYELOMA; NEUTROPHIL; OUTPATIENT DEPARTMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FILGRASTIM; GRAFT SURVIVAL; HEMATOLOGIC NEOPLASMS; HUMANS; KINETICS; MALE; MIDDLE AGED; MYELOPOIESIS; NEUTROPENIA; NEUTROPHILS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 21244460393     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704994     Document Type: Article

References (11)

1. Bearman SI, Appelbaum FR, Back A et al. Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 1989; 7: 1288-1294.
2. Schmitz N, Dreger P, Zander AR et al. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995; 15: 261-266.
3. Bence-Bruckler I, Bredeson C, Atkins H et al. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant 1998; 22: 965-969.
4. Molineux G, Kinstler O, Briddell B et al. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999; 27: 1724-1734.
5. Molineux G. Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy 2003; 23: 3S-8S.
6. Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 2004; 10: 1235-1244.
7. IBMTR Core Instruction Manual 2/2002, version 2, pp 22-23.
8. Holmes FA, Jones SE, O'Shaughnessy J et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002; 13: 903-909.
9. Holmes FA, O'Shaughnessy JA, Vukelja S et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle vs daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727-731.
10. Green MD, Koelbl H, Baselga J et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim vs daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29-35.
11. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-2555.